BREASTOZ 2.5 TABLET

Product Description

BREASTOZ 2.5 TABLET is a high-quality pharmaceutical formulation containing Letrozole 2.5mg, widely prescribed as an aromatase inhibitor for the treatment of hormone receptor-positive breast cancer in postmenopausal women. Manufactured under strict quality control standards, BREASTOZ offers consistent performance, high efficacy, and excellent patient compliance.

Key Benefits:

• Effective in hormone-dependent breast cancer management

• Reduces estrogen levels to inhibit tumor growth

• Well-tolerated oral tablet form for convenient dosing

• Manufactured with GMP-compliant processes ensuring purity and potency

Usage & Indication:
BREASTOZ 2.5 TABLET is indicated primarily for:

• First-line treatment of postmenopausal women with hormone receptor-positive or unknown locally advanced or metastatic breast cancer

• Adjuvant treatment of early breast cancer in postmenopausal women

• Extended adjuvant treatment after standard tamoxifen therapy

Target Buyers:

• Pharmaceutical wholesalers and distributors

• Oncology medicine retailers and pharmacy chains

• Hospital procurement departments

• Bulk medicine exporters and stockists

Why Choose BREASTOZ?

• Competitive pricing for bulk purchase

• Stable shelf-life for long-distance distribution

• Backed by regulatory certifications and reliable sourcing

• Strong demand in domestic and international markets for oncology and hormonal therapy portfolios